Julie Clor
About Julie Clor
Julie Clor is a scientist with extensive experience in immunology and multi-color flow cytometry. She has worked at several research institutions, including EMD Millipore and Luminex Corporation, and currently serves as a scientist at Arcus Biosciences.
Work at Arcus Biosciences
Julie Clor has been employed at Arcus Biosciences as a Scientist since 2021. In this role, she contributes to the company's research and development efforts in the field of immunology. Arcus Biosciences focuses on advancing cancer therapies, and Clor's expertise in immune systems plays a significant role in their projects. Her work involves applying her knowledge of multi-color flow cytometry and cell culture to support the development of innovative treatments.
Previous Experience in Research
Before joining Arcus Biosciences, Julie Clor worked at Luminex Corporation as a Senior Research Scientist from 2006 to 2021. During her tenure, she focused on various research initiatives related to immunology. Prior to that, she was a Research Associate III at Gladstone Institutes from 2004 to 2006, where she contributed to significant research projects in the San Francisco Bay Area. Clor also held a position as a Research Associate at Alloway from 1998 to 2000, further building her foundation in biological research.
Education and Expertise
Julie Clor earned her Bachelor of Science (B.S.) degree in Biology from Ohio Northern University, where she studied from 1994 to 1998. Her academic background laid the groundwork for her professional expertise in immunology. Clor possesses specialized skills in multi-color flow cytometry, a technique essential for analyzing the characteristics of particles in a fluid. She also has strong capabilities in cell culture, which involves maintaining and growing cells in controlled environments.
Research Contributions and Publications
Julie Clor has actively contributed to the scientific community through her research. In November 2023, she presented her research at the Society for Immunotherapy of Cancer (SITC) conference, highlighting her ongoing engagement in the field. Additionally, she co-authored a publication on AB598, a CD39 inhibitory antibody, which focuses on promoting immune-mediated tumor control. This work reflects her commitment to advancing cancer immunotherapy.